:surufatinibcamrelizumab

Yong Li1,2,3, Jinpeng Huang1,2,3, Xian Chen1,2

  • 1Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Frontiers in oncology
|July 26, 2024
PubMed
概括

不分化的小圆细胞肉瘤 (uSRCSs) 具有挑战性治疗. 一名患有晚期USRCS的患者在多次先前治疗失败后对surufatinib和camrelizumab产生了积极反应,实现了26个月的无进展生存期.